Take Homes in Lung Cancer

Healio spoke with Melina Elpi Marmarelis, MD, about data from the INSIGHT 2 trial presented at this year’s International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Melina Elpi Marmarelis, MD, discussed research on the use of osimertinib versus durvalumab following chemoradiation in patients with stage III EGFR-mutated NSCLC.

Osimertinib plus chemotherapy may benefit some lung cancer subsets compared with osimertinib alone, according to recent research from the FLAURA2 trial.

Healio spoke with Melina Elpi Marmarelis, MD, about key takeaways from the MARS 2 trial presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

In this video, Hossein Borghaei, DO, MS, discusses safety, response and survival data of patients with small cell lung cancer who received tarlatamab, a half-life extended bispecific T-cell engager, or HLE BiTE.

At this year’s International Association for the Study of Lung Cancer World Conference on Lung Cancer, one of the more talked about presentations was IMpower010.

In this video, Andrew Ciupek, PhD, spoke with Healio about non-treatment-related presentations from at the World Conference on Lung Cancer.

In this video, Andrew Ciupek, PhD, discusses findings from the Alliance trial, IMpower010 and NADIM-2.

Andrew Ciupek, PhD, spoke with Healio about real-world barriers to clinical trial enrollment for patients with lung cancer in the United States.

Narjust Florez (Duma), MD, discusses results from two studies presented at World Conference on Lung Cancer — IMpower010 and NADIM-2